Medtronic plc (BCBA:MDT)
Argentina · Delayed Price · Currency is ARS | Market Cap | 178.43T +13.9% |
| Revenue (ttm) | 55.92T +9.8% |
| Net Income | 7.79T +12.3% |
| EPS | 6,046.70 +12.1% |
| Shares Out | n/a |
| PE Ratio | 22.90 |
| Forward PE | 15.34 |
| Dividend | 790.98 (2.16%) |
| Ex-Dividend Date | Sep 25, 2026 |
| Volume | 290 |
| Open | 36,580 |
| Previous Close | 36,680 |
| Day's Range | 36,160 - 36,860 |
| 52-Week Range | 27,380 - 41,500 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 1, 2026 |
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and rem... [Read more]
Financial Performance
In fiscal year 2026, Medtronic's revenue was $36.36 billion, an increase of 8.43% compared to the previous year's $33.54 billion. Earnings were $4.80 billion, an increase of 2.98%.
Financial numbers in USD Financial StatementsNews
Dividend Aristocrat Stocks PEP and MDT Attract 10%+ Upside Targets Ahead of Key September Dates
Analysts see at least 10% upside in dividend aristocrat stocks PepsiCo ($PEP) and Medtronic ($MDT). This matters as the companies have ex-dividend dates of Friday, September 4, 2026, and Friday,…
Medtronic price target raised to $92 from $78 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Medtronic (MDT) to $92 from $78 and keeps a Hold rating on the shares.
Medtronic price target raised to $110 from $100 at UBS
UBS raised the firm’s price target on Medtronic (MDT) to $110 from $100 and keeps a Buy rating on the shares.
Medtronic price target raised to $115 from $100 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Medtronic (MDT) to $115 from $100 and keeps an Outperform rating on the shares. Cardiovascular products continue to drive Medtronic’s…
Medtronic price target raised to $99 from $86 at Truist
Truist raised the firm’s price target on Medtronic (MDT) to $99 from $86 and keeps a Hold rating on the shares. The company reported a solid Q1 revenue beat and…
Medtronic price target raised to $104 from $102 at Wells Fargo
Wells Fargo raised the firm’s price target on Medtronic (MDT) to $104 from $102 and keeps an Overweight rating on the shares. The firm notes the company reported a strong…
Medtronic price target raised to $110 from $95 at BofA
BofA raised the firm’s price target on Medtronic (MDT) to $110 from $95 and keeps a Buy rating on the shares. Almost every business unit ex-CAS has a growth driver…
Medtronic price target raised to $95 from $80 at Stifel
Stifel analyst Rick Wise raised the firm’s price target on Medtronic (MDT) to $95 from $80 and keeps a Hold rating on the shares. Medtronic “delivered on its promise” for…
Medtronic price target raised to $100 from $91 at Baird
Baird raised the firm’s price target on Medtronic (MDT) to $100 from $91 and keeps a Neutral rating on the shares. The firm updated its model following results which showed…
6 Dividend Aristocrats to Play Right Now
Medtronic, McCormick and T. Rowe Price are among the stocks that have outperformed the S&P 500 over the past three months—and have dividend yields of at least 3%.
Medtronic CEO Martha on beating estimates in Q1: Driven by growth across many of our businesses
Geoff Martha, Medtronic CEO, joins 'Squawk on the Street' to discuss shares rising Tuesday after the company announced a $700 million investment in Cornerstone Robotics, a robotic surgical company.
Medtronic price target raised to $100 from $91 at BTIG
BTIG raised the firm’s price target on Medtronic (MDT) to $100 from $91 and keeps a Buy rating on the shares following the company’s Q1 results. The news regarding Medtronic’s…
Midday Fly By: Medtronic reports Q1 beat, Ternus takes over as Apple CEO
The major averages were broadly lower to start the month of September as inflation concerns and rising oil prices lifted bond yields in the U.S. and elsewhere. Worries continue to…
Medtronic Lifts Outlook, Invests Over $700 Million in Heart Tech & Robotics
Medtronic raised its outlook for the year after posting higher fiscal first-quarter profit and sales, driven by broad-based demand and contributions from newer growth platforms.
Medtronic Earnings Call Transcript: Q1 2027
Q1 FY27 saw 13.7% organic revenue growth to $9.8B and adjusted EPS of $1.45, with broad-based strength across major business units and significant contributions from CAS, Altaviva, and robotics. FY27 guidance was raised for both revenue and EPS, supported by strong execution and innovation.
Medtronic Earnings release: Q1 2027
Medtronic released its Q1 2027 earnings on September 1, 2026, summarizing the period's financial results.
Medtronic Slides: Q1 2027
Medtronic has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on September 1, 2026.
Medtronic Quarterly report: Q1 2027
Medtronic has published its Q1 2027 quarterly earnings report on September 1, 2026.
Medtronic Stock Rises on Better-Than-Expected Earnings and $700 Million Investment in a Robot Surgeon
Medtronic stock advances after the company posts better-than-expected quarterly earnings, raises revenue guidance, and announces a $700 million investment.
Medtronic reports Q1 non-GAAP EPS $1.45, consensus $1.39
Reports Q1 revenue $9.8B, consensus $9.54B. “We are off to a strong start in fiscal 2027. What gives us confidence is not simply the strength of the quarter, but importantly,…
Medtronic announces $700M investment in Cornerstone Robotics
Medtronic (MDT) announced a strategic partnership with Cornerstone Robotics. The approximately $700M investment includes rights to distribute Cornerstone Robotics’ Sentire surgical system in select ma...
Medtronic narrows FY27 EPS view to $5.94-$6.00 from $5.90-$6.00
Consensus $5.95. Raises FY27 organic revenue view to up 7.25%-7.75% from 6.75%-7.25%. “We continue to make targeted investments in innovation, portfolio development, and commercial execution that will...
Medtronic boosts fiscal 2027 forecasts on heart device demand
Medtronic raised the lower end of its fiscal 2027 profit forecast and revenue growth outlook on Tuesday, banking on strong demand for its heart devices used in complex cardiovascular procedures.
Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance
Strength across the company's largest franchises, new growth platforms, and recent portfolio investments support the long-term growth trajectory GALWAY, Ireland, Sept. 1, 2026 /PRNewswire/ -- Medtroni...
Medtronic announces $80M investment in Pi-Cardia
Medtronic (MDT) and Pi-Cardia announced a strategic investment by Medtronic in Pi-Cardia. With a focus on addressing the evolving needs of increasingly complex transcatheter aortic valve replacement p...